GILEAD SCIENCES SL
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 122
- Registration Number
- NCT02120300
Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
Phase 2
Completed
- Conditions
- Ventricular Arrhythmia
- Interventions
- Drug: Placebo to match eleclazine
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 313
- Registration Number
- NCT02104583
- Locations
- 🇺🇸
Cardiovascular Associates of Mesa, Mesa, Arizona, United States
🇺🇸Ohiohealth Corporation, Columbus, Ohio, United States
🇺🇸Charlotte Heart and Vascular Institute, Port Charlotte, Florida, United States
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection
Phase 2
Completed
- Conditions
- Chronic Genotype 5 HCVChronic Genotype 4 HCV
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 85
- Registration Number
- NCT02081079
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 11
- Registration Number
- NCT02077465
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸University at Buffalo CTRC, Buffalo, New York, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 117
- Registration Number
- NCT02074514
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 335
- Registration Number
- NCT02073656
Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 79
- Registration Number
- NCT02071082
- Locations
- 🇺🇸
Be Well Medical Center PC, Berkley, Michigan, United States
🇺🇸AHF Research Center, Beverly Hills, California, United States
🇺🇸Barry M. Rodwick MD, Clearwater, Florida, United States
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Phase 2
Terminated
- Conditions
- B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT02044822
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
Phase 3
Completed
- Conditions
- Chronic HCV Infection
- Interventions
- Drug: LDV/SOF
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 384
- Registration Number
- NCT02021656
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 687
- Registration Number
- NCT02021643
© Copyright 2025. All Rights Reserved by MedPath